A rapid and sensitive gas-liquid chromatographic procedure for the micro determination of sodium valproate (sodium di-N-propylacetate) in plasma or serum

Fellenberg, A. J.; Pollard, A.C.

doi:10.1016/0009-8981(77)90012-2

Cited by 18 publications

(5 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The determination of the plasma concentrations of drugs was performed according to the following methods: progabide (Gillet et al, 1980), carbamazepine and its epoxide (Rovei et al, 1980), phenobarbital (Sichler and Pippenger, 1978), sodium valproate (Fellenberg and Pollard, 1977).…”

Section: Monitoring Of Plasma Concentrations Of Drugsmentioning

confidence: 99%

Progabide Treatment in Severe Epilepsy: A Double‐Blind Cross‐over Trial Versus Placebo

Martínez‐Lage

Bossi²,

Morales

et al. 1984

Epilepsia

View full text Add to dashboard Cite

Twenty therapy-resistant epileptic patients entered a double-blind, randomized, two-period, cross-over trial comparing progabide (19.3-36 mg/kg/day) and placebo as add-on drugs to standard therapy. Each period lasted 6 weeks with a gradual crossover during 4 days. Five patients were dropped because of reasons unrelated to treatment. Among the 15 patients who completed the study, seven had partial, six primary generalized, and two secondary generalized epilepsies. Preexisting antiepileptic drugs (AEDs) ranging from one to three per patient (mean 2.2 AEDs/patient) were maintained unchanged during the trial. Efficacy was assessed biweekly by means of total seizure counts, counts of each seizure type, and global clinical judgment. At the same time intervals, safety was assessed by means of reports of adverse events, clinical and neurological examination, laboratory tests, and measurement of plasma concentrations of progabide and associated AEDs. According to the clinical global judgment, eight patients were considered improved during progabide treatment. Seizures were reduced in 14 of 15 patients during the progabide as compared with the placebo period. During the progabide period, the reduction of the total seizure count was 45 and 58% in two patients and 88-97% in six patients. A significant reduction of the total seizure number was observed in the progabide period as compared with the placebo period, both in the whole patient group (p less than 0.01) and in the two subgroups of patients with generalized (p less than 0.01) and partial (p less than 0.05) epilepsies.(ABSTRACT TRUNCATED AT 250 WORDS)

show abstract

Section: Monitoring Of Plasma Concentrations Of Drugsmentioning

confidence: 99%

Progabide Treatment in Severe Epilepsy: A Double‐Blind Cross‐over Trial Versus Placebo

Martínez‐Lage

Bossi²,

Morales

et al. 1984

Epilepsia

View full text Add to dashboard Cite

show abstract

“…Another possibility is the use of the solid, non-hygroscopic molecular complex, consisting of equimolecular amounts of valproic acid and its sodium salt.The amount of serum which is needed for gas chromatographic valproate assay vanes between 0.1 and 1.0 ml in most methods. Samples of only 0.05 ml serum have been analyzed after extraction into 0.05 ml n-heptane by Fellenberg et al(77). Jacobs et al(78) have described a procedure in which 0.02 ml serum, after precipitation of the protein with 0.01 ml diluted HCI, was injected directly into the column.…”

mentioning

confidence: 99%

Review of Procedures Used for Aed Monitoring

2009

Acta Neurologica Scandinavica

View full text Add to dashboard Cite

“…Chlorinated solvents readily extract FBM at any pH, but FBM cannd be analyzed by GC because it is nonvolatile and decomposes to styrene at high temperatures. A method for determination of VPA in 0.025-0.050 ml human plasma by acid extraction into n-hexane and direct injection using packed-column GC has been reported (Fellenberg and Pollard, 1977).…”

mentioning

confidence: 99%

Determination of Valproate in the Presence of Felbamate in Human Plasma by Narrow Bore Capillary Gas Chromatography

et al. 1994

View full text Add to dashboard Cite

A narrow bore capillary gas chromatographic method with one extraction step has been developed for quantitation of valproate (VPA) in the presence of felbamate (FBM) in human plasma. The method uses 0.250-ml aliquots of human plasma and one internal standard (IS). Chromatographic conditions include a DBWAX, 0.25 mm ID x 15 m, 0.25-micron film thickness column; splitless injection; and flame ionization detection. The linear quantitation range for VPA is 1.00-256 micrograms/ml.

show abstract

A rapid and sensitive gas-liquid chromatographic procedure for the micro determination of sodium valproate (sodium di-N-propylacetate) in plasma or serum

Cited by 18 publications

References 7 publications

Progabide Treatment in Severe Epilepsy: A Double‐Blind Cross‐over Trial Versus Placebo

Progabide Treatment in Severe Epilepsy: A Double‐Blind Cross‐over Trial Versus Placebo

Review of Procedures Used for Aed Monitoring

Determination of Valproate in the Presence of Felbamate in Human Plasma by Narrow Bore Capillary Gas Chromatography

Contact Info

Product

Resources

About